Form 4: Clearside Biomedical CFO Acquires 200,000 Stock Options
SEC Form 4 Filing
Charles A. Deignan, CFO of Clearside Biomedical, Inc., acquired 200,000 employee stock options on January 8, 2025.
Summary
- Charles A. Deignan, the Chief Financial Officer of Clearside Biomedical, Inc., filed a Form 4 on January 10, 2025.
- The filing reports a transaction that occurred on January 8, 2025, where Deignan acquired 200,000 employee stock options.
- These options have an exercise price of $0.97.
- One-fourth of the shares underlying the options vest on January 8, 2026, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, simply reporting a transaction.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings in the company's stock.
Stakeholder Impact
- The acquisition of stock options by the CFO could be seen as a positive signal by shareholders, indicating confidence in the company's future performance.
- Employees may view this as a positive sign of management's commitment.
Key Dates
| Date | Description |
|---|---|
| 01/08/2025 | Date of transaction: CFO acquired 200,000 employee stock options. |
| 01/08/2026 | Vesting start date: One-fourth of the shares underlying the options vest. |
| 01/08/2035 | Expiration date of the employee stock options. |
| 01/10/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.